- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05259085
Study of ALXN2050 in Participants With Hepatic Impairment
A Phase 1, Open-Label, Multiple-Dose, Parallel Study to Determine the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of ALXN2050 in Adult Participants
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Alexion Pharmaceuticals, Inc.
- Phone Number: 855-752-2356
- Email: clinicaltrials@alexion.com
Study Locations
-
-
Florida
-
Hialeah, Florida, United States, 33014
- Recruiting
- Clinical Trial Site
-
Orlando, Florida, United States, 32809
- Recruiting
- Clinical Trial Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Body weight must be at least 50.0 kilograms (kg) and body mass index (BMI) within the range of 18.0 - 40.0 kg/meter squared (inclusive) at the time of signing the informed consent.
- Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Must agree to receive prophylactic antibiotics to mitigate the potential risk of meningococcal infection.
Participants with Impaired Hepatic Function
- Aside from IHF, sufficiently healthy for study participation based upon medical history, physical examination, neurological examination, laboratory tests, vital signs, and electrocardiograms (ECGs).
Score on the Child-Pugh scale at screening as follows:
- Mild: Class A (Child-Pugh score ≥5 and ≤6); or
- Moderate: Class B (Child-Pugh score ≥7 and ≤9); or
- Severe: Class C (Child-Pugh score ≥10 and ≤15).
- Diagnosis of chronic (>6 months), stable (no acute episodes of illness within the previous 1 month due to deterioration in hepatic function) hepatic insufficiency.
- Must be on a stable medication regimen. Concomitant medications must be approved by Alexion unless presented in the list of common concurrent medications for participants with IHF.
- Cirrhosis, as evidenced by parenchymal liver disease by biopsy (histological diagnosis), imaging test, or other suitable imaging study, due to chronic hepatitis C virus (HCV) infection, chronic hepatitis B infection, cryptogenic, alcohol abuse, or non-alcoholic steatohepatitis.
No evidence of hepatocellular carcinoma as documented by imaging within 6 months prior to the first dose of study intervention.
Matched Healthy Control Participants with Normal Hepatic Function
- Must match the sex (similar ratio) and race (similar ratio of white and non-white) of participants with IHF; age must be within ± 10 years and BMI must be within ± 20% of participants with IHF at screening.
- Healthy as determined by medical evaluation including medical history, physical examination, neurological examination, laboratory tests, vital signs, and ECGs.
Exclusion Criteria:
- History or presence of seizures, head injury, head trauma, or any other brain disorder.
- History of procedures that could alter absorption or excretion of orally administered drugs.
- History of meningococcal infection or a first-degree relative with a history of meningococcal infection.
- Body temperature ≥38.0°Celcius at screening or check-in or history of febrile illness or other evidence of infection, systemic or otherwise, within 14 days prior to the first dose of study intervention.
- Classical pathway hemolysis results outside the reference ranges at screening, unless approved by Alexion.
- Significant blood loss or donation of blood within 3 months prior to the first dose of study intervention, donation of plasma within 30 days prior to the first dose of study intervention, receipt of blood products within 6 months prior to first dose of study intervention, or receipt of a vaccine within 30 days prior to the first dose of study intervention.
- Current enrollment or past participation within the last 30 days (or 5 half-lives, whichever is longer) prior to the first dose of study intervention in the current clinical study or any other clinical study involving an investigational study intervention or any other type of medical research.
- Pregnant or lactating.
- History or presence of drug or alcohol abuse within 6 months prior to the first dose of study intervention, current tobacco user, or positive results for alcohol and/or drug screen at screening or check-in.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 4: Healthy Control
Participants will receive ALXN2050.
|
ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
Other Names:
|
Experimental: Cohort 1: Mild IHF
Participants will receive ALXN2050.
|
ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
Other Names:
|
Experimental: Cohort 2: Moderate IHF
Participants will receive ALXN2050.
|
ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
Other Names:
|
Experimental: Cohort 3: Severe IHF
Participants will receive ALXN2050.
|
ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area Under The Concentration-time Curve From Time 0 To The 12-hour Time Point (AUC0-12) Of Plasma ALXN2050 After Steady-state
Time Frame: Up to 72 hours postdose
|
Up to 72 hours postdose
|
Area Under The Concentration-time Curve Calculated To The Last Observable Concentration At Time t (AUCt) Of Plasma ALXN2050 After Steady-state
Time Frame: Up to 72 hours postdose
|
Up to 72 hours postdose
|
Time To Reach Maximum (Peak) Plasma Concentration Following ALXN2050 Administration At Steady-state (Tmax,ss)
Time Frame: Up to 72 hours postdose
|
Up to 72 hours postdose
|
Maximum (Peak) Steady-state Plasma Concentration Of ALXN2050 (Cmax,ss)
Time Frame: Up to 72 hours postdose
|
Up to 72 hours postdose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number Of Participants Receiving ALXN2050 With Treatment-emergent Adverse Events
Time Frame: Day 1 (postdose) through follow-up (30 [+/- 2] days after last study drug administration)
|
Day 1 (postdose) through follow-up (30 [+/- 2] days after last study drug administration)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ALXN2050-HV-109
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on ALXN2050
-
Alexion PharmaceuticalsCompleted
-
AlexionRecruiting
-
AlexionCompleted
-
Alexion Pharmaceuticals, Inc.TerminatedGeneralized Myasthenia Gravis | Myasthenia GravisUnited States, Italy, Spain, Canada, Germany, Korea, Republic of, Serbia, Taiwan
-
AlexionActive, not recruitingParoxysmal Nocturnal Hemoglobinuria (PNH)United Kingdom, Italy, Canada, Korea, Republic of, New Zealand, Spain, Turkey
-
Alexion PharmaceuticalsCompleted
-
Alexion PharmaceuticalsAchillion, a wholly owned subsidiary of AlexionCompleted
-
Alexion Pharmaceuticals, Inc.RecruitingLupus Nephritis | Immunoglobulin A Nephropathy | IgAN | LNAustralia, Spain, United Kingdom, China, Germany, Italy, Argentina, Peru, Korea, Republic of, Taiwan, Thailand, United States, Serbia, Israel, Brazil, Turkey, Mexico, Russian Federation
-
Alexion PharmaceuticalsCompleted
-
Alexion PharmaceuticalsAchillion, a wholly owned subsidiary of AlexionCompleted